In brief
Key points
- Mounjaro contains tirzepatide; Wegovy contains semaglutide.
- Mounjaro’s indication is type 2 diabetes.
- Wegovy has weight-management and other defined indications.
The direct answer
Mounjaro is a tirzepatide diabetes product. Wegovy is a semaglutide product with several current indications. Weekly administration does not make the products equivalent.[1][2]
| Question | Mounjaro | Wegovy |
|---|---|---|
| Ingredient | Tirzepatide | Semaglutide |
| Receptor activity | GIP and GLP-1 | GLP-1 |
| Route / frequency | Injection / weekly | Injection / weekly |
| Current indication focus | Adults with type 2 diabetes | Weight management plus defined cardiovascular and conditional MASH roles |
Why headline percentages are weak shortcuts
Separate trials can differ in population, indication, dose, duration and outcome. Cross-trial numbers cannot establish a universal winner. Even direct evidence must be interpreted for the relevant indication and individual.[1][2]
Compare products that match the treatment question
For type 2 diabetes, the Mounjaro–Ozempic page aligns two diabetes product contexts. For tirzepatide weight management, Zepbound is the product-specific guide.[3][4]
Access is product-specific
Check the exact DIN with the plan and the exact prescription with a pharmacy. A clinical comparison and an access comparison answer different questions.
Evidence
Sources
- Mounjaro (tirzepatide injection) Product MonographHealth Canada / Eli Lilly Canada · Checked August 14, 2026
- Wegovy (semaglutide injection) Product MonographHealth Canada / Novo Nordisk Canada · Checked August 14, 2026
- Ozempic (semaglutide injection) Product MonographHealth Canada / Novo Nordisk Canada · Checked August 14, 2026
- Zepbound (tirzepatide injection) Product MonographHealth Canada / Eli Lilly Canada · Checked August 14, 2026
- Understanding health insuranceFinancial Consumer Agency of Canada · Checked August 14, 2026